Disclosures for "PRAX-562 is a Well-Tolerated, Novel Persistent Sodium Channel Blocker with Broad Anticonvulsant Activity in Multiple DEE Mouse Models")
-
Dr. Anderson has received personal compensation for serving as an employee of Praxis Precision Medicines.
-
Nikola Jancovski has nothing to disclose.
-
Dr. Eckert has received personal compensation for serving as an employee of Praxis Precision Medicines. Dr. Eckert has received personal compensation for serving as an employee of Janssen Research & Development, LLC. Dr. Eckert has stock in Praxis Precision Medicines. Dr. Eckert has stock in Janssen Research and Development. Dr. Eckert has received intellectual property interests from a discovery or technology relating to health care.
-
The institution of Dr. Baker has received research support from Praxis Precision Medicines, Inc.
-
Mr. Wagley has nothing to disclose.
-
Snezana Maljevic has nothing to disclose.
-
Christopher Reid has nothing to disclose.
-
Dr. Patel has received personal compensation for serving as an employee of GenEP. Dr. Patel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Gep Ep. Dr. Patel has stock in GenEP.
-
Prof. Kearney has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PTC Therapeutics. Prof. Kearney has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine Biosciences. The institution of Prof. Kearney has received research support from NIH. The institution of Prof. Kearney has received research support from Dravet Syndrome Foundation. The institution of Prof. Kearney has received research support from Lennox Gastaut Foundation. The institution of Prof. Kearney has received research support from Pfizer. The institution of Prof. Kearney has received research support from Neurocrine Biosciences. The institution of Prof. Kearney has received research support from Praxis Precision Medicines. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care. Prof. Kearney has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Kahlig has received personal compensation for serving as an employee of Praxis Precisoin Medicines. Dr. Kahlig has stock in Praxis Precision Medicines.
-
Steven Petrou has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Praxis Precision Medicines. Steven Petrou has stock in Praxis Precision Medicines. The institution of Steven Petrou has received research support from Praxis Precision Medicines. The institution of Steven Petrou has received research support from Medical Research Future Fund. Steven Petrou has received intellectual property interests from a discovery or technology relating to health care. Steven Petrou has received intellectual property interests from a discovery or technology relating to health care.